Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 11Genitourinary 7Gastrointestinal 7Gynecologic 4Thoracic 1Other solid neoplasm 1

Conditions

Lung Neoplasms 1

Interventions

Carboplatin 181pembrolizumab 156Pemetrexed 129Cisplatin 97Drug Therapy 67Paclitaxel 59osimertinib 56Magnetic Resonance Spectroscopy 50durvalumab 49Specimen Handling 49Radiotherapy 49Nivolumab 49atezolizumab 43Docetaxel 43Etoposide 40Bevacizumab 39Blood Specimen Collection 33tislelizumab 31Radiosurgery 31Gemcitabine 29130-nm albumin-bound paclitaxel 27Immunotherapy 25Immune Checkpoint Inhibitors 25cemiplimab 23Injections 23aflutinib 20Cetuximab 18Biopsy 18Standard of Care 17Platinum Compounds 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × disitamab vedotin × Thoracic × Clear all
NCT06749860 2024-12-27

Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression

Shanghai Pulmonary Hospital, Shanghai, China

Phase 2 Recruiting
58 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡